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Background: A large proportion of patients with bipolar disorder experience persistent cognitive dysfunction, such
as memory, attention and planning difficulties, even during periods of full remission. The aim of this trial is to
investigate whether cognitive remediation, a new psychological treatment, improves cognitive function and, in
turn, psychosocial function in patients with bipolar disorder in partial or full remission.
Methods/Design: The trial has an evaluator-blind, randomized, between-groups design. Forty patients with bipolar
disorder in full or partial remission, aged 18 to 50 years, who report moderate to severe cognitive difficulties, are
recruited. Patients are randomized to receive weekly group-based cognitive remediation treatment over 12 weeks
in addition to standard treatment or standard treatment alone. Both groups undergo neurocognitive testing and
functional magnetic resonance imaging (fMRI) at baseline, post-treatment (week 12) and follow-up (week 26). The
primary outcome is improved verbal memory, as measured with the Rey Auditory Verbal Learning Test (RAVLT) from
baseline to post-treatment. With inclusion of 40 patients we obtain 86% power to detect a clinically relevant
difference in verbal memory between groups. Secondary outcomes are improved attention, executive function and
psychosocial function, as measured with the Rapid Visual Information Processing test, the Trail Making Test part B
and the Functional Assessment Short Test (FAST), respectively. Tertiary outcomes are improved scores for additional
neuropsychological tests of memory, attention, executive function and facial expression recognition, as well as in
questionnaires measuring subjective cognitive difficulties, stress, coping strategies, personality traits, depressive
symptoms and quality of life.
Discussion: This is the first randomized controlled trial to evaluate the effects of cognitive remediation on
cognitive function in patients with bipolar disorder who experience persistent cognitive difficulties despite being in
full or partial remission.
Trial registration: ClinicalTrials.gov NCT01457235.
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Worldwide, bipolar disorder (BD) is among the ten lead-
ing causes of reduced functional ability [1]. Despite med-
ical treatment with mood stabilizers, newer antipsychotics
and antidepressants, a large proportion of patients with
BD experience persistent and debilitating cognitive dys-
function [2-4]. In particular, trait-related deficits have been
shown in verbal memory, sustained attention and execu-
tive function [5,6], as well as in social cognition [7,8].
These cognitive deficits may not simply be side effects of
the medical treatment but may also represent a core fea-
ture of the psychopathology [9,10]. It has been estimated
that 30 to 60% of bipolar patients have trait-related cogni-
tive deficits and that these reduce their occupational and
social functioning [11-13] and quality of life [14]. There is
an urgent clinical need for new treatment strategies that
target cognitive enhancement in BD.
Cognitive remediation (CR) is a new psychological
treatment, which aims to improve cognitive function,
compensation and coping skills and, consequently, psy-
chosocial function. It has been studied extensively in
patients with schizophrenia: a recent meta-analysis of 40
studies demonstrated that CR leads to lasting improve-
ment of cognitive and social function levels in this pa-
tient group (effect size = 0.45; 95% confidence interval =
0.31 to 0.59) [15]. Another meta-analysis of 16 studies of
CR in mixed groups of patients with affective disorders,
affective psychosis, schizophrenia or schizoaffective disor-
ders suggests that patients with BD can achieve beneficial
effects of CR that are equivalent to those observed in pa-
tients with schizophrenia (effect size = 0.32; 95% confi-
dence interval = 0.20 to 0.43) [16]. Four of these studies
included patients with affective disorders; of these, one
study in unipolar disorder showed that memory improve-
ment following CR was associated with increased occupa-
tional function [17]. Similarly, improved psychosocial and
occupational functioning was found in a small, uncon-
trolled trial of 18 patients with BD [18] and in a small,
controlled trial with a mixed sample of patients with uni-
polar depression and BD [19] with large effect size; (partial
η2 = 0.45). Nevertheless, the studies included in the meta-
analysis provide only preliminary evidence.
Recently, a multicentre randomized controlled trial
(RCT) investigated the effects of functional remediation
versus either psychoeducation or standard care on psy-
chosocial function in euthymic patients with BD [20].
Although patients in the functional remediation group
showed functional improvement compared with those in
standard care (with small effect size; d′ = 0.3), this was
not significantly different from the improvement ob-
served in the psychoeducation group. In addition, assess-
ment of cognitive function revealed no beneficial effects
of functional remediation over psychoeducation or
standard care [20].The aim of this trial is, therefore, to investigate whether
CR has beneficial effects on cognitive and psychosocial
function in patients with fully or partially remitted BD
who experience persistent cognitive difficulties. The ra-
tionale for inclusion of this remitted patient group is that
their trait-related cognitive deficits are not successfully
targeted by current treatments, as opposed to the state-
related deficits in acute affective episodes, which may in
some cases resolve fully with affective symptom reduction
[2-4]. Beneficial effects on trait-related cognitive deficits
would hence point to future implementation of CR for
remitted patients with BD, in order to facilitate these pa-
tients’ cognitive abilities and capacity to cope with educa-
tion, work and everyday functioning.
Hypotheses
The hypotheses of the present study are that CR, in
comparison with standard treatment, will:
1. Enhance verbal memory (primary outcome), as
measured with the Rey Auditory Verbal Learning
Test (RAVLT) from baseline to week 12.
2. Improve sustained attention, executive function and
psychosocial function (secondary outcomes), as
measured with the Rapid Visual Information
Processing, Part B of the Trail Making Test and
Functional Assessment Short Test (FAST).
3. Improve additional measures of attention, executive
function and facial expression recognition, as
measured with a comprehensive neurocognitive test
battery; and improve self-reported cognitive and
psychosocial function, as measured with
questionnaires.
Biomarkers of treatment effects
In addition, we wish to investigate the following biomarkers
of potential beneficial effects of CR on the outcome param-
eters: plasma levels of brain derived neurotrophic factor
(BDNF), stress response, as reflected by morning awaken-
ing cortisol levels, and the neuroanatomical underpinnings
of memory, attention, executive function and emotional
processing. We hypothesize that potential beneficial effects
of CR are associated with an increase in levels of plasma
BDNF, a reduction in levels of morning awakening cortisol,
or changes in the neuroanatomical underpinnings of mem-
ory, attention, executive function and emotional processing
(see details under section ‘Brain biomarkers of potential
treatment effects’), or a combination of these.
Methods/Design
Study design
Patients will be randomized (1:1) to receive either CR in
a group setting or standard treatment in an evaluator-
blind between-groups design.
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Patients will mainly be recruited through the Copenhagen
Affective Disorder Clinic, Psychiatric Centre Copenhagen,
Copenhagen University Hospital, Rigshospitalet, Copenhagen,
Denmark. The centre receives patients with complex
affective disorders from the whole capital region. Patients
will receive written information about the project and will
be given the opportunity to ask questions before deciding
whether to participate. Further information is available
during the entire course of investigation from any of
the researchers involved in the project. Patients will
be screened with a medical check and a psychiatric
interview using Schedules for Clinical Assessment in
Neuropsychiatry [21] to confirm diagnosis, and the 17-
item Hamilton Depression Rating Scale, (HDRS-17) [22]
and the Young Mania Rating Scale (YMRS) [23] to deter-
mine the severity of depressive and manic symptoms.
We will recruit a minimum of 44 patients with the as-
sumption of a 10% dropout rate, leaving us with 40 com-
pleters. We include patients with BD (as defined by
ICD-10 diagnostic criteria), aged 18 to 50 years, who are
in full or partial remission (defined as HDRS-17 and
YMRS scores of ≤14) and have subjective complaints of
cognitive difficulties of moderate to severe degree (score
of ≥4) in at least two of seven cognitive domains on the
Massachusetts General Hospital Cognitive and Physical
Functioning Questionnaire [24]. Exclusion criteria are:
current ECT-treatment, current substance or alcohol
abuse, schizophrenia, schizoaffective disorder or significant
suicide risk. Patients are permitted to take antidepressants,
lithium, antipsychotic medication and benzodiazepines
corresponding to <22.5 mg Oxazepam daily.
Interventions
Cognitive remediation treatment
Patients randomized to the CR group will receive CR in
addition to standard treatment. A group of clinical psy-
chologists at the Copenhagen Affective Disorder Clinic
manualized the CR treatment. The CR programme is
based on a treatment programme for patients with schizo-
phrenia [25], experience with cognitive rehabilitation in
brain damage and thorough clinical and research-based
knowledge of cognitive difficulties in BD. Before study ini-
tiation, we conducted a small pilot study, including six pa-
tients between September and December 2009, with the
purpose of testing and revising the treatment manual and
session structure and to define treatment length. The CR
was then designed to consist of 12 weekly group sessions
of two hours each, followed by a booster session four
weeks after treatment completion. Groups include be-
tween five and eight patients and are run by two group
therapists; a specialist in psychiatry with more than
20 years of clinical expertise with bipolar patients and a
clinical psychologist trained in neuropsychology.The programme has three main components: (1) psy-
choeducation and awareness of cognitive dysfunction in
BD, including an emphasis on discovering each patient’s
individual profile of cognitive dysfunction; (2) training of
compensatory and adaptive strategies in relation to cogni-
tive dysfunction; and (3) computer-assisted cognitive
training using RehaCom [26]. The computerized exercises
chosen for our intervention target attention and concen-
tration, memory and learning, and executive function.
Most exercises are highly ecologically valid as they
focus on everyday life situations, thereby optimizing the
translation from computer training to real-life cognitive
demands, for example, planning activities, shopping for
groceries, counting, memorizing short articles or memor-
izing people’s faces and their names, job titles and phone
numbers. The level of difficulty is automatically custom-
ized to each patient and increases as the patients’ per-
formance improves. Furthermore, employing computer
exercises as part of the treatment provides easily access-
ible homework and enables an individually tailored
training programme to be created despite the group-
based intervention.
A number of general principles for the CR sessions
were established and are followed by the group thera-
pists to facilitate learning: therapists will give brief lec-
tures on a given topic without the use of PowerPoint
slides, to minimize the strain on the patients’ divided at-
tention. To account for the patients’ limited attention
spans, the therapists are allowed to talk for a maximum
of 5 to 10 minutes without patient involvement, after
which patients are required to engage actively in the ses-
sion. Each session consists of 120 minutes including a
15 minutes break. Homework, which practises attention,
memory and executive function, consists of computer
training, mindfulness exercises and reading a textbook
about cognitive dysfunction in BD. Occasionally, the use
of new compensatory and adaptive strategies will be in-
cluded as part of the homework between sessions. Home-
work assignments will be discussed in each session along
with planning of how the patient can most easily succeed
in fulfilling the assignments at home. This includes plan-
ning the time of day and for how long each patient will
read and complete the assigned computer tasks. For the
homework reading tasks, each section of the book is
assigned as homework twice, in order to facilitate the ap-
plication of adaptive and compensatory strategies as well
as to enhance the possibility of learning and remembering
the contents.
The 12 sessions are divided into four main topics. The
first two sessions consist of an introduction to cognitive
function and dysfunction and to the principles of CR. In
sessions three to five, attention and concentration are the
main focus. An emphasis is placed on the importance of
attention as a foundation for other areas of cognitive
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sessions are psychoeducation on the variation in atten-
tional function in BD, basic neuropsychological knowledge
concerning various aspects of attentional function, com-
puter training, and compensatory and adaptive strategies.
Examples of such strategies for enhancing attentional
function are reading with and without background music
in order to discover what works best, allowing frequent
breaks during attention straining tasks, such as setting an
alarm when reading, and limiting oneself to carry out one
task at a time rather than attempt to multitask a number
of activities or initiate new activities before other activities
are completed. Finally, therapists train patients in mind-
fulness meditation as a means to enhance attentional cap-
acity [27], and in subsequent sessions, a brief mindfulness
meditation will be carried out at the beginning of each
session.
Sessions six to eight address memory and learning.
During these sessions, various exercises on remembering
visual and auditory verbal input are performed. These
exercises include a reading task where patients are
handed a brief newspaper article on a relevant topic ten
minutes before the 15 minutes break during a session.
The timing is chosen to ensure a small time gap between
encoding and recall of the content of the article. Patients
are asked to read the article with the intention of giving
a brief resume in front of the rest of the group after the
break. Before commencing the task, we refresh memory
techniques, such as reading aloud, taking brief notes and
using visual imagery in order to remember key points.
Another exercise is a conversational task, also carried
out just before the 15 minutes break during sessions. In
this exercise, patients work in pairs; one of them pretend-
ing to be a close friend or relative and the other asking
questions to get to know this person. Again, following the
15 minutes break they are asked to tell the rest of the
group about the person they had ‘interviewed’. The idea of
pretending to be another person is to ensure that the lis-
tening patient does not have prior knowledge of the con-
versation partner.
Brief talks are given on various aspects of memory,
such as long-term versus short-term memory and work-
ing memory, and verbal versus visuospatial memory.
An introduction to establishing structure in everyday
life is followed by homework on this topic. Home-
work includes establishing a routine of using only one
calendar or diary, whether it is an electronic version
or a traditional paper version, rather than several,
which may cause confusion. Furthermore, patients are
instructed in efficient use of a diary or calendar by includ-
ing all appointments plus time for rest and physical
exercise, grocery shopping, and so on. Possible cogni-
tive side effects of medication and substance abuse
are discussed.Sessions 9 to 12 are dedicated to executive function in
everyday life. Thorough discussions of where executive
dysfunction arises provide a foundation for individual-
ized homework assignments in order to improve these
areas of functioning. In the sessions, we carry out trou-
bleshooting as a group-based exercise. One patient men-
tions a problem, such as being incapable of cooking a
meal or always being late for appointment and feeling
stressed as a result. With thorough guidance from the
group therapists, we break down the problem into as
many subcomponents as possible and try to conjure
up new and creative solutions to try out as homework
in between sessions. The homework assignments are
followed up in great detail. Also, at this point in the
treatment programme, reading of fiction as cognitive
training of attention and verbal memory is introduced.
Each patient is encouraged to choose a book as a home-
work assignment and a detailed plan for the reading
process is established. An emphasis is placed on making
the treatment programme as individualized as possible.
Standard treatment group
Patients in the control group receive standard treatment
consisting of the standard out-patient mental health ser-
vices routines in the capital region of Denmark either at
the Copenhagen Affective Disorder Clinic, community
psychiatric centres or private specialists in psychiatry.
Standard treatment involves psychopharmacological mood
stabilization and relapse prevention and, in our clinic and
most community psychiatric centres, psychoeducation. In
contrast to the intervention group, standard treatment
does not involve any specific cognitive training.
Randomization
Pharma Consulting Group [28] performed the randomization
of the patients with stratification for age (<35 years) and
years of education (<15 years).
Blinding
Study personnel involved in the evaluation of outcomes
are blinded to treatment allocation. Blinding is main-
tained throughout the study, data management, outcome
assessment and data analysis.
Outcome assessments
The main study outcomes (cognitive and psychosocial
function) and biomarkers of potential treatment effects
(plasma BDNF, cortisol levels and neuroanatomical un-
derpinnings) will be measured at baseline, after comple-
tion of treatment (week 12) and at follow-up (week 26).
We also rate affective symptoms at these three time
points and additionally at weeks 6 and 20 to uncover
potential mood swings in the periods between out-
come assessments.
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Patients undergo neurocognitive testing with a compre-
hensive test battery including the following RAVLT sub-
tests: total recall across the five learning trials (I to V),
RAVLT recall following interference (trial VI), recall fol-
lowing a 30 minute delay and recognition from baseline to
week 12 [29,30]; Trail Making Test parts A and B [31];
Repeatable Battery of the Assessment of Neuropsychological
Status digit span and coding [32]; WAIS-III Letter-Number
Sequencing [33]; Verbal and Semantic Fluency Tests [34];
Danish Adult Reading Test [35]; the computerized Facial
Expression Recognition Task test from the Oxford
Emotional Test Battery (P1Vital; Oxford); and the following
computerized tests from Cambridge Cognition (CANTAB):
Simple Reaction Time; Rapid Visual Information Pro-
cessing; Delayed Match-to-Sample; and Spatial Work-
ing Memory.
Psychosocial function
Psychosocial function will be measured with FAST [36],
which is specifically developed and validated for BD.
Questionnaires
Self-reported cognitive difficulties, stress, coping strat-
egies, personality traits, depressive symptoms and quality
of life are measured using the following questionnaires:
Massachusetts General Hospital Cognitive and Physical
Functioning Questionnaire; State-Trait Anxiety Inventory
[37]; Eysenck Personality Questionnaire [38]; Coping
Inventory for Stressful Situations [39]; Language and
Words; Cognitive Failures Questionnaire [40]; World
Health Organization Quality of life BREF [41]; Cohen’s
Perceived Stress Scale [42]; Positive and Negative Affect
Scales [43]; European Quality of Life-5 Dimensions [44];
Beck Depression Inventory [45] and Work and Social
Adjustment Scale [46].
Brain biomarkers of potential treatment effects
The neuroanatomical underpinnings of potential benefi-
cial cognitive effects of CR are explored with functional
and structural magnetic resonance imaging (fMRI and
MRI) at baseline and weeks 12 and 26. In particular, we
will investigate whether CR modulates neural responses
underlying memory, executive function and social cogni-
tion with a picture encoding task (revised from Miskowiak
et al. [47]), an N-back (2-back versus 0-back) working
memory task, and an emotional face processing task using
fearful and happy NimStim faces. We hypothesize that the
CR group compared with the standard treatment group
will (1) increase memory-related activation in medial tem-
poral regions including the hippocampus and that this
will correlated with memory performance; (2) enhance
neural response in a fronto-parietal network during the 2-
back task, which is associated with improved executivefunction; and (3) modulate neural responses to emo-
tional faces in a fronto-limbic circuitry, which is accom-
panied by improved facial expression recognition. In
addition, we will explore whether CR induces changes in
hippocampus structure, white matter fibre structure and
brain connectivity.
Imaging data analysis
Both fMRI and MRI data are collected with a Siemens
Trio scanner operating at 3.0 T at the Danish Research
Centre for Magnetic Resonance, Hvidovre Hospital,
Denmark. Image analysis is carried out using tools from
FMRIB Software Library [48,49]. BET is used for brain
extraction of the T1-weighted images and FLIRT is used
to perform affine alignment of the diffusion and T1-
weighted images. The FIRST tool, which is part of
FMRIB’s Software Library version 5.0 [48], is used to
segment the hippocampus automatically for analyses of
changes in volume and shape. The fMRI data from the
memory and emotion processing tasks will preprocessed
and analyzed using FMRIB Expert Analysis Tool version
6.0, part of FMRIB Software Library, whilst fMRI data
from the N-back task will preprocessed and analyzed
using Statistical Parametric Mapping software version 8.
Region-of-interest analyses of prefrontal, limbic and par-
ietal regions, as well as exploratory whole-brain analyses
will be performed. Diffusion images will be analyzed
using tools from FMRIB Diffusion Toolkit. Probabilistic
modelling of diffusion parameters and tractography are
carried out using previously described methods [50].
In particular, we will compare differences in neural ac-
tivity from baseline to post-treatment between CR and
standard treatment groups for patients who have com-
pleted both baseline and post-treatment scanning sessions.
In addition, cross-sectional post-treatment comparisons
between the groups will be made in the event of missing
data at baseline. Pearson’s coefficients are calculated to de-
termine the relationship between MRI changes and neuro-
psychological improvements.
Sample size and power calculation
Test sample and statistical power is calculated by nQuery
Advisor 5.0 software. The primary outcome is a change in
verbal memory measured with RAVLT from baseline to
week 12 between CR and standard treatment groups. A
recent study demonstrated that the average California
Verbal Learning Test (a verbal learning test equivalent
to the RAVLT) total recall score for patients with remitted
BD is 52.0, whilst the score for healthy age-matched con-
trol subjects was 60.7 (out of a maximum 75) [51]. Based
on this, we would expect a clinically relevant difference in
the change between groups to be at least 4 points in
RAVLT total recall. Assuming an average RAVLT total re-
call score of 56 subsequent to CR and 52 (that is, a
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ard treatment and a standard deviation of 4 points for
both groups, a sample size of N = 40 patients (N = 20 per
group) will achieve a statistical power of 86% to demon-
strate a clinically relevant verbal memory improvement
with CR versus standard treatment.
Statistical analyses of primary, secondary and tertiary
outcomes
To investigate the effects of CR versus standard treat-
ment from baseline to week 12 (primary outcome assess-
ment time), we will use repeated measures analysis of
covariance with adjustment for stratification variables,
and with and without adjustment for mood changes
from baseline to week 12. To investigate long-term ef-
fects of CR versus standard treatment in week 26, we
will implement a linear mixed-effects model with ran-
dom intercept for each participant, structured as a two-
level model specifying a correlation of samples within
participants, with adjustment for stratification variables,
and with and without adjustments for mood changes.
Significant interactions will be analyzed further with
simple main effect analyses. All statistical analyses of
behavioural data, mood ratings and questionnaires
will be performed using the Statistical Package for Social
Sciences.
Ethical considerations
The study is approved by The Regional Committee on
Biomedical Research Ethics (protocol number H-1-2010-
039), The Danish Data Protection Agency (protocol
number 2010-41-4710) and ClinicalTrials.gov (identifier
NCT01457235).
Discussion
This trial is the first RCT to investigate the effects of CR
on cognitive function in BD. Data from patients with
schizophrenia and preliminary results from small explora-
tory studies in mixed groups of patients with affective dis-
orders suggest beneficial effects [16-19], although a recent
study of functional remediation in BD showed no signifi-
cant effect on cognition [20]. The present trial therefore
serves to meet the clinical need for more specific and
thorough investigations of the effects of CR on patients’
cognitive function.
Limitations
CR in a group setting has been investigated in only a few
studies [15,20] and it is unclear whether group therapy
is less appealing than individual therapy for patients with
cognitive difficulties. It is, however, our experience from
the pilot study and patient feedback from the present
trial that patients benefit from group-based training; it is
often easier for patients to acknowledge and accept theirown cognitive difficulties and to learn to cope with them
when they are aware of other patient’s problems and im-
provements. Another limitation is that it is unclear how
many training sessions are optimal for bipolar patients
with cognitive dysfunction. In an uncontrolled study by
Deckersbach et al. [18], 14 individual sessions of CR
were provided and results showed lower residual symp-
toms and increased occupational and overall psychosocial
functioning in patients with BD. Moreover, improvements
in executive functioning were associated with improved
occupational functioning. Studies of patients with schizo-
phrenia have typically included an average treatment
length of 32.2 hours (range = 4 to 130 hours), provided
over 16.7 weeks (range = 2 to 104 weeks) with a therapy
intensity of 2.2 sessions per week (range = 0.6 to 5 sessions
per week) [15].
We chose to provide 12 + 1 sessions based on the ex-
perience from our pilot study that this length is suffi-
cient for improvement in most patients. However, if this
first exploratory study finds an effect of CR on cognition,
future studies are warranted to explore the optimal
length of treatment and frequency of CR sessions. Fi-
nally, the choice of a good control group is often com-
plicated in psychological intervention studies. We chose
to compare CR as an add-on to standard treatment with
standard treatment alone. With such a design we cannot
be sure that a potential beneficial effect of the active
intervention is due specifically to the CR program or to
an unspecific effect of solely taking part in group ses-
sions. Colom et al. [52] used an elegant, if time- and
resource-consuming, design by comparing group psy-
choeducation with unspecific group intervention in their
seminal paper aiming to detect the specific effects of
psychoeducation. It can be argued whether the interaction
between patients in the unspecific group intervention is
comparable to part of the CR treatment. Using our design,
the entire combined effect of CR and group sessions, in-
cluding the interaction with other patients with similar
problems in group sessions, is investigated.
Advantages
RAVLT was chosen as the primary outcome measure for
the following reasons: (a) remitted patients with BD show
deficits on this test [53,54]; (b) it is a standardized, inter-
nationally accepted and valid test of verbal memory [55];
(c) there is a high correlation between verbal memory and
psychosocial function [56], which makes it clinically rele-
vant; and (d) other RCTs have found significant effects of
CR on verbal memory in patients with schizophrenia
[57-59]. However, there is also consistent evidence for
trait-related deficits in sustained attention in BD and
negative effects of this on psychosocial function [56]. In
addition, CR has been shown to improve attention in
schizophrenia [57,59] and unipolar disorder [17], and both
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our CR programme. Therefore, the priority of verbal
memory over sustained attention as the primary outcome
may be somewhat arbitrary.
The study has a naturalistic approach with few exclu-
sion criteria. Patients should have BD, should be in
complete or partial remission and should self-report
cognitive difficulties. To make treatment with CR mean-
ingful, patients with current substance or alcohol abuse
or significant suicide risk are excluded but standard psy-
chopharmacological treatment is allowed. Consequently,
if CR is found to produce beneficial effects, the interven-
tion can be implemented to treat all bipolar patients in
complete or partial remission with subjective complaints
of cognitive difficulties. We expect a high patient accept-
ance and adherence as the CR program is easy to follow
and not too time consuming and also because of the
supportive positive effects from the group setting in it-
self. From a feasibility perspective, the intervention is
relatively inexpensive as two therapists in our affective
disorder clinic deliver the group sessions. Although the
CR intervention is standardized according to a manual
and the computer training software [26] it is likely that
treatment with CR is best offered in specialized affective
disorder clinics with expertise within pharmacological
and psychological treatment of BD.
Perspectives
If CR proves effective, it can easily be implemented in fu-
ture treatment of BD to facilitate patients’ cognitive func-
tion and thereby potentially improve their psychosocial
function.
Trial status
Patient enrolment started in September 2011 and is on-
going until a minimum 40 patients have completed assess-
ment at week 12 (primary outcome assessment time).
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